Skip to content

Study · Non-randomized trial · 1994

3 results

Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study.

Mathias JR, Clench MH, Reeves-Darby VG, Fox LM, Hsu PH, Roberts PH, Smith LL, Stiglich NJ

Digestive diseases and sciences1 Jun 1994Cited by 59 (Europe PMC)

PMID8200247 (opens in a new tab)DOI10.1007/bf02093778 (opens in a new tab)PepBankPUB-08200247
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with functional bowel disease, nausea, vomiting, bloating, abdominal pain, early satiety and overall symptom scores improved during leuprolide treatment (P < 0.01-0.05).

    In plain wordsDuring leuprolide treatment, women had improved nausea, vomiting, bloating, abdominal pain, early satiety and overall symptom scores.

    Peptide
    Leuprolide
    Outcome
    DecreaseGastrointestinal symptom scores and overall symptoms
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    3.75 mg monthly · intramuscular · three monthsAs given in this study (human).

    Source sentences

    Summary
    Patients treated with low-dose leuprolide improved progressively and significantly in scores for nausea, vomiting, bloating, abdominal pain, and early satiety, and for overall symptoms (P < 0.01-0.05).
    4 context sentences
    Summary · context
    We prospectively investigated the effect of a gonadotropin-releasing hormone analog, leuprolide acetate, in 30 women with symptoms of moderate to severe functional bowel disease.
    Summary · context
    The study was phase II, randomized, double blind, and placebo controlled.
    Summary · context
    Lupron Depot 3.75 mg (which delivers a continuous low dose of drug for one month) or placebo were given intramuscularly monthly for three months.
    Summary · context
    Follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone levels were assessed before and after therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with functional bowel disease, FSH, estradiol and progesterone decreased significantly during leuprolide treatment (P < 0.05).

    In plain wordsFSH, estradiol and progesterone decreased significantly during leuprolide treatment in women with functional bowel disease.

    Peptide
    Leuprolide
    Outcome
    DecreaseFSH, estradiol and progesterone
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg monthly · intramuscular · three monthsAs given in this study (human).

    Source sentences

    Summary
    All hormone levels decreased significantly (P < 0.05) except luteinizing hormone (P = 0.054).
    4 context sentences
    Summary · context
    We prospectively investigated the effect of a gonadotropin-releasing hormone analog, leuprolide acetate, in 30 women with symptoms of moderate to severe functional bowel disease.
    Summary · context
    The study was phase II, randomized, double blind, and placebo controlled.
    Summary · context
    Lupron Depot 3.75 mg (which delivers a continuous low dose of drug for one month) or placebo were given intramuscularly monthly for three months.
    Summary · context
    Follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone levels were assessed before and after therapy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with functional bowel disease, luteinizing hormone did not decrease significantly during leuprolide treatment (P = 0.054).

    In plain wordsLuteinizing hormone did not show a significant decrease during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeLuteinizing hormone
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg monthly · intramuscular · three monthsAs given in this study (human).

    Measurements

    P value
    0.054
    LH change

    Source sentences

    Summary
    All hormone levels decreased significantly (P < 0.05) except luteinizing hormone (P = 0.054).
    4 context sentences
    Summary · context
    We prospectively investigated the effect of a gonadotropin-releasing hormone analog, leuprolide acetate, in 30 women with symptoms of moderate to severe functional bowel disease.
    Summary · context
    The study was phase II, randomized, double blind, and placebo controlled.
    Summary · context
    Lupron Depot 3.75 mg (which delivers a continuous low dose of drug for one month) or placebo were given intramuscularly monthly for three months.
    Summary · context
    Follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone levels were assessed before and after therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.